Contemporary Oncology
eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Original paper

In silico approach and in vitro study of fangchinoline-induced apoptosis and reactive oxygen species production in HER2-overexpressing breast cancer cells

Denny Satria
1
,
Poppy Anjelisa Zaitun Hasibuan
2
,
Masfria Masfria
3
,
Syukur Berkat Waruwu
4
,
Choo Yeun-Mun
5
,
Feri Eko Hermanto
6
,
Nashi Widodo
7

  1. Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia
  2. Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia
  3. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia
  4. Pharmacist Professional Education, Faculty of Pharmacy and Health Sciences, Universitas Sari Mutiara Indonesia, Medan, Indonesia
  5. Department of Chemistry, Faculty of Science, Universiti Malaya, Kuala Lumpur, Malaysia
  6. Division of Computational Biology, Faculty of Animal Sciences, Universitas Brawijaya, Malang, Indonesia
  7. Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Malang, Indonesia
Contemp Oncol (Pozn) 2026; 30 (1)
DOI: https://doi.org/10.5114/wo.2026.159783
Online publish date: 2026/03/03
Article file
- In silico approach.pdf  [4.61 MB]
Get citation
 
PlumX metrics:
 
1. Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol 2021; 18: 663-672.
2. Hunter N, English E, Nguyen V, Vinayak S, Linden HM, Specht JM, et al. Experiences of patients with metastatic breast cancer: a qualitative study. JCO Oncol Pract 2023; 19: 346-346.
3. Yang J, Ju J, Guo L, Ji B, Shi S, Yang Z, et al. Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning. Comput Struct Biotechnol J 2022; 20: 333-342.
4. Tapia M, Hernando C, Martínez MT, Burgués O, Tebar-Sánchez C, Lameirinhas A, et al. Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies. Cancers (Basel) 2023; 15: 4522.
5. Ward RA, Fawell S, Floc’h N, Flemington V, McKerrecher D, Smith PD. Challenges and opportunities in cancer drug resistance. Chem Rev 2021; 121: 3297-3351.
6. Asma ST, Acaroz U, Imre K, Morar A, Ali Shah AR, Hussain SZ, et al. Natural products/bioactive compounds as a source of anticancer drugs. Cancers 2022; 14: 6203.
7. Yuan M, Zhang G, Bai W, Han X, Li C, Bian S. The role of bioactive compounds in natural products extracted from plants in cancer treatment and their mechanisms related to anticancer effects. Oxid Med Cell Longev 2022; 1-19.
8. Fakhri, S, Moradi SZ, Moradi SY, Piri S, Varnamkhasti BS, Piri S, et al. Phytochemicals regulate cancer metabolism through modulation of the AMPK/PGC-1 signaling pathway. BMC Cancer 2024; 24: 1079.
9. Hasibuan PAZ, Sitorus RKUAB, Hermawan A, Huda F, Waruwu SB, Satria D. Anticancer activity of the ethylacetate fraction of Vernonia amygdalina Delile towards overexpression of HER-2 breast cancer cell lines. Pharmacia 2024; 71: 1-8.
10. Korkmaz Aİ, Bal C, Eraslan EC, Sevindik M, Akgul H. Biological activities of Agrocybe praecox (spring fieldcap mushroom). Prospect. Pharm. Sci. 2023; 21: 33-39.
11. Saha D, Sarankar SK. Critical review on potentials of ethnopharmacological, ethnomedicinal and traditional practices of Madhuca longifolia (J. Koenig Ex L.) J. F. Macbr. (Family: Sapotaceae). Prospect Pharm Sci 2023; 21: 30-36.
12. Tafrihani AS, Hanif N, Yoga IMBK, et al. A computational study of cardiac glycosides from Vernonia amygdalina as PI3K inhibitors for targeting HER2 positive breast cancer. J Comput Aided Mol 2025; 39: 43.
13. Zhang J, Gao X, Liu C, Wang MX, Zhang RR, Sun JY, et al. Design, synthesis and in vitro evaluation of fangchinoline derivatives as potential anticancer agents. Bioorg Chem 2020; 94: 103431.
14. Jiang Y, Liu M, Liu H, Liu S. A critical review: traditional uses, phytochemistry, pharmacology and toxicology of Stephania tetrandra S. Moore (Fen Fang Ji). Phytochem Rev 2020; 19: 449-489.
15. Cao X, Miao X, Ge M, Zhang M, Lv Z, Wang W, et al. Exploration of habitat-related chemical markers for Stephania tetrandra applying multiple chromatographic and chemometric analysis. Molecules 2022; 27: 7224.
16. Yang J, Hu S, Wang C, Song J, Chen C, Fan Y, et al. Fangchinoline derivatives induce cell cycle arrest and apoptosis in human leukemia cell lines via suppression of the PI3K/AKT and MAPK signaling pathway. Eur J Med Chem 2020; 186: 111898.
17. Ma Z, Liu Y, Peng H, Liang C, Zhang Y, Ma Z, et al. History of uses, phytochemistry, pharmacological activities, quality control and toxicity of the root of Stephania tetrandra S. Moore: a review. J Ethnopharmacol 2020; 260: 112995.
18. Chan EWC, Wong SK, Chan HT. An overview on the chemistry, pharmacology and anticancer properties of tetrandrine and fangchinoline (alkaloids) from Stephania tetrandra roots. J Integr Med 2021; 19: 311-316.
19. Zhang W, Yu X, Bao L, He T, Pan W, Li P, et al. Bisbenzylisoquinoline alkaloid fangchinoline derivative HY-2 inhibits breast cancer cells by suppressing BLM DNA helicase. Biomed. Pharmacother 2023; 169: 115908.
20. Wang B, Long S, Lan J, Luo K, Zhang W, Li X, et al. Derived from fangchinoline, LYY-35 exhibits an inhibiting effect on human NSCLC cancer A549 cells. J Cancer 2024; 15: 4232-4243.
21. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. J Chem Inf Model 2021; 61: 1549-9596.
22. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. In: Hempel J, Williams C, Hong C (eds.). Chemical biology. Methods in molecular biology, 1263. Humana Press, New York, NY 2015.
23. Syahraini A, Harnelly E, Hermanto FE. Pro-apoptosis activity of Pogostemon cablin Benth. against nasopharyngeal carcinoma through the BCL-2 inhibition signaling pathway: a computational investigation. Makara J Sci 2021; 27.
24. Hermanto FE, Warsito W, Rifa’i M, Widodo M. Understanding hypocholesterolemic activity of soy isoflavones: Completing the puzzle through computational simulations. J. Biomol Struct Dyn 2022; 41: 9931-9937.
25. Susilo A, Cahyati M, Nurjannah N, Pranovo D. Chrysin inhibits Indonesian serotype foot-and-mouth-disease virus replication: insights from DFT, molecular docking and dynamics analyses. J Trop Biodivers Biotechnol 2024; 9: 83140.
26. Satria D, Hasibuan PAZ, Muhammad M, Waruwu SB, Utomo RY, Ghoran SH. Cytotoxic and apoptotic effect of Vernonia amygdalina Delile. fractions against Hs578t triple-negative breast cancer cell lines. Phytomedicine Plus 2024; 4: 100640.
27. Chatri M, Hasibuan PAZ, Meiyanto E. Effect of African leaves (Vernonia amygdalinaDelile) on the development of T47D breast cancer cells. Trop J Nat Prod Res 2024; 8: 7740-7746.
28. Satria D, Waruwu SB, Sholikhah EN, Mustofa M, Satriyo PB, Wahyuningsih TD, et al. The activity of pyrazoline B compound in inhibiting proliferation of breast cancer cells with human epidermal growth factor receptor 2 overexpression. Contemp Oncol 2025; 29: 360-366.
29. Satria D, Silalahi J, Haro G, Ilyas S, Zaitun Hasibuan PA. Cytoprotective activity of ethylacetate fraction of Picria fel-terrae Lour. herbs. Open Access Maced J Med Sci 2019; 7: 3865-3867.
30. Schillaci R, Guzmán P, Cayrol F, Beguelin W, Flaqué MCD, Proiet- ti CJ, et al. Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer 2012; 12: 74.
31. He L, Lv S, Ma X, Jiang S, Zhou F, Zhang Y, et al. ErbB2 promotes breast cancer metastatic potential via HSF1/LDHA axis-mediated glycolysis. Med Oncol 2022; 39: 45.
32. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2020; 19: 6102-6114.
33. Parakh S, Gan HK, Parslow AC, Burvenich IJG, Burgess AW, Scott AM. Evolution of anti-HER2 therapies for cancer treatment. Cancer Treat Rev 2017; 59: 1-21.
34. Zhang Y. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. Pharmacol Ther 2021; 218: 107677.
35. Rousseau B, Tirupathur A, Murugan S, Sarkar DK. Abstract 3440: Beta-2 adrenergic receptors role in tumor aggressiveness of MDA-MB- 231 breast cancer cells. Cancer Res 2019; 79: 3440-3440.
36. Caparica R, Ma Y, Angelis CD, Richard F, Desmedt C, Awada A, et al. Beta-2 adrenergic receptor gene expression in HER2-positive early-stage breast cancer patients: a post-hoc analysis of the NCCTG-N9831 (alliance) trial. Clin Breast Cancer 2022; 22: 308-318.
37. Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E, et al. Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer. Clin Breast Cancer 2020; 20: 262-273.e7.
38. Wei X, Chen L, Yang A, Lv Z, Xiong M, Shan C. ADRB2 is a potential protective gene in breast cancer by regulating tumor immune microenvironment. Transl Cancer Res 2021; 10: 5280-5294.
39. Farabaugh SM, Boone DN, Lee AV. Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation. Front Endocrinol (Lausanne) 2016; 6.
40. Lee JS, Tocheny CE, Shaw LM. The Insulin-like growth factor signaling pathway in breast cancer: An elusive therapeutic target. Life 2022; 12: 1992.
41. Wang P, Mak VCY, Cheung LWT. Drugging IGF-1R in cancer: new insights and emerging opportunities. Genes Dis 2023; 10: 199-211.
42. Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer 2021; 7: 56.
43. Schroeder R, Stevens C, Sridhar J. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. Molecules 2014; 19: 15196-15212.
44. Zhang Y, Qi D, Gao Y, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res 2024; 12: 16.
45. Cao Y, Li Y, Liu R, Zhou J, Wang K. Preclinical and basic research strategies for overcoming resistance to targeted therapies in HER2-positive breast cancer. Cancers (Basel) 2023; 15: 2568.
46. Koutova D, Kulhava M, Havelek R, Majorosova M, Královec K, Habartova K, et al. Bersavine: A novel bisbenzylisoquinoline alkaloid with cytotoxic, antiproliferative and apoptosis-inducing effects on human leukemic cells. Molecules 2020; 25: 964.
47. Gao XZ, Lv XT, Zhang RR, Luo Y, Wang MX, Chen JS, et al. Design, synthesis and in vitro anticancer research of novel tetrandrine and fangchinoline derivatives. Bioorg Chem 2021; 109: 104694.
48. Ruzinova MB, Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol 2003; 13: 410-418.
49. Husna F, Hasibuan PAZ, Sitorus P, Satria D, Waruwu SB, Damayanti E, et al. Revealing the anti-breast cancer potential of essential oil from jungga orange peel (Citrus jambhiri): Network pharmacology and in vitro studies. Trends Sci 2025; 23: 11289.
50. Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 2023; 22: 138.
51. Dalimunthe A, Harahap U, Silalahi J, Silalahi J, Satria D. Phytochemicals constituent and antipancreatic cancer activity of ethanol extract of Litsea cubeba Lour. Fruits. Rasayan J Chem 2021; 14, 41-45.
52. Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, Wet al. Oxidative stress in cancer cell metabolism. Antioxidants 2021; 10: 642.
53. Molina MA, Codony-Servat J, Albanell J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749.
54. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer cell 2006; 10: 25-38.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
RG
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.